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Background: Most data on outcomes in Idiopathic Pulmonary Fibrosis (IPF) pre-dates current
guidelines. Data on rates of infection is sparse; the effect of low-dose corticosteroids and dis-
ease severity is unknown.
Methods: We identified randomised-controlled trials of IPF and analysed rates of mortality,
lower respiratory tract infections (LRTIs), IPF progression and acute exacerbations from the pla-
cebo arms. We standardised event rates and compared differences using incidence rate ratios
(IRRs) between subgroups according to disease severity or use of low-dose immunosuppression.
Results: Mortality was lower in trials that recruited patients with mild-moderate disease sever-
ities only, as compared to trials where patients with severe disease were allowed (188.6 vs 78.6
deaths per 1000 patient/years, IRR 0.30e0.59,p< 0.0001). No statistical differencewas seenbe-
tween trials permitting and excluding low-dose prednisolone use. LRTIs were found to be com-
moner in trials allowing low dose prednisolone use compared with those that did not (227.1 vs
63.4 infections per 1000 patient/years. IRR 2.56e5.13, p< 0.0001), andwere less frequent in tri-
als excluding patients with severe disease (153.9 vs 257.8 infections per 1000 patient/years, IRR
0.45e0.81, pZ 0.0003). Acute exacerbations occurred less frequently in trials excluding severe
disease (28.2 vs 122.9 exacerbations per 1000 patient/years, IRR 0.11e0.55, p< 0.0001). There
was no difference between groups in rates of IPF progression.
Conclusion: Mortality is heterogeneous and dependent on entry criteria. Infection rates were
high, both with and without immunosuppression, and were higher in severe disease. Consider-
ation should be given to alternative outcomes to mortality in future IPF trials if severe disease
is excluded.
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Outcomes from idiopathic pulmonary fibrosis trials 377Introduction
Idiopathic Pulmonary Fibrosis (IPF) is a progressive and
incurable form of interstitial lung disease resulting in
fibrosis of the parenchyma. Epidemiological data suggests
that the incidence is 6.8e16.3 per 100,000 [1], with high
mortality [2], though this is based on patients with a diag-
nostic criteria that precedes current international guide-
lines from 2000 [3], and the 2011 update [4]. It has also
been recently suggested by the European IPF consensus
group that mortality in randomised trials studying IPF is
much lower than expected, and too low for its use as a
primary outcome in future trials [5]. It is therefore unclear
if IPF patients enrolled in clinical trials reflect the prognosis
and progression of IPF patients seen in the clinic.
The incidence of significant symptoms associated with
IPF is not fully known. The incidence of acute exacerba-
tions of IPF is unknown [6] but the proportion of patients
suffering this event was calculated to be 8.5% in one year
from a study of 147 patients [7]. Bacterial infections may
have an important implication in the pathogenesis or
prognosis of IPF [8], but frequency of these events is
unknown.
In the search for effective treatments, several large
randomised, placebo-controlled trials have been performed
recently. Although few have shown evidence of benefit (n-
acetylcysteine [9], pirfenidone [10] and BIBF-1120 [11]), a
pooled analysis of outcomes in the control arms represents
a unique opportunity to evaluate the natural history of IPF
in a large cohort of patients undergoing rigorous follow-up.
A comprehensive synthesis of the well-characterised pa-
tients within the RCTs allows quantitative evaluation of a
broad range of patient oriented outcomes such as rates of
disease progression, acute exacerbations, infections and
mortality. In view of previous findings of increased mor-
tality with immunosuppression [12] and the debate about
endpoints for clinical trials [5,13], we were interested in
the outcomes of studies depending on whether inclusion
criteria permitted immunosuppression or stated disease
severity.Methods
Literature search and selection
This review incorporated all double-blind, placebo-
controlled RCTs, investigating any pharmacological treat-
ment for IPF. The population of interest was patients with
IPF of any severity, diagnosed using radiology or biopsy,
who were enrolled in the placebo arms of these trials.
A systematic search was performed of MEDLINE, EMBASE,
AMED and Cochrane central. A search was performed using
the terms “Idiopathic pulmonary fibrosis” or “IPF” or “Usual
interstitial pneumonia” or “UIP,” and “Randomised” or
“Randomized,” and “Placebo”. The returned results were
screened for appropriate trials by the first author by
reviewing each abstract. Trials considered potentially
suitable for inclusion were reviewed in full. Bibliographies
of relevant articles were reviewed to identify any addi-
tional papers.Data extraction
The pre-specified outcomes of interest were rates of mor-
tality (all-cause and respiratory causes where quoted),
lower respiratory tract infections, pneumonia (where re-
ported as a specific and separate event to ‘lower respira-
tory tract infections’), progression of diseases (defined as a
reduction in Forced Vital Capacity (FVC) by 10% or DLco
(diffusing capacity of carbon monoxide) by 15% within the
course of the trial), and acute exacerbations of IPF (where
listed as a separate entity within trial outcomes and
adverse events). Data regarding the outcomes was extrac-
ted, as well as baseline characteristics, enrolment criteria
for participants, whether immunosuppression was allowed
and how many patients were on steroids, and methods of
follow-up where available.
Validity assessment
One reviewer rated the methodological quality of each
study using the five-point Jadad score for RCTs [14]. Bias
was assessed using the ‘Risk of Bias’ tool provided by the
Cochrane collaboration.
Statistical analysis
Standardised event rates were calculated for each
outcome. The number of events occurring during follow-up
were normalised to give a rate per 1000 patient-years of
follow-up. We also conducted random effects meta-analysis
of proportion of patients affected per year for each spec-
ified outcomes (standardised to rates occurring per 1000
patient/years of follow-up).
For subgroup analysis according to different categories
of patients, we classified trials into those including mild-to-
moderate disease only, which were defined as trials speci-
fying a lower-limit cut-off value for FVC or DLco at baseline
(Table 1), versus those including all severities. The cut-off
values are displayed in Table 1. Trials were also classified
into those allowing concurrent use of immunosuppression or
not. Trials allowing low-dose corticosteroids were defined
as those including patients on steady doses of prednisolone
not more than 20 mg. One paper [33] was included despite
two patients receiving daily prednisolone doses greater
than 20 mg. We compared the event rates in different
groups of trials by calculated incidence rate ratios (IRRs)
and 95% confidence intervals using MedCalc for Windows,
version 12.2 (MedCalc Software, Ostend, Belgium).
Results
Literature search
In total, 118 abstracts were screened for suitability. Of
these, 20 full-text articles were reviewed for eligibility.
Four trials were not placebo controlled and were excluded
[9,15e17]. Two trials were excluded because the trials
were stopped early and the average length of follow-up was
not given [12,18]. One trial was excluded [19] as it predated
latest guidelines for IPF diagnosis [3] and the diagnosis of
IPF could not be confirmed. In total, thirteen trials were
Table 1 Trial designs and inclusion/exclusion criteria for the randomised controlled trials included in this review.
Trial Investigated
agent
Placebo
arm (n)
Patient/
years
follow-up
Age (yrs)
(Mean  SD)
Male
sex
(%)
Time since
diagnosis
(years)
(mean  SD)
FVC
baseline
(% pred)
(mean)
Dlco
baseline
(% pred)
(mean)
Ever
smokers
(%)
Current
smokers
(%)
Receiving
steroids
(%)
Inclusion criteria
Shulgina et al., e
2012 [36,37]
Co-trimoxazole 86 86 70.7  8.6 69.5 2.6  4.7 71.5 39.1 72 (75.8%) 1 (1.1%) 52 (60.5) Evidence of clinical
decline. No restriction;
only two patients on
>20 mg prednisolone.
Richieldi et al., e
2011 [11]
BIBF-1120 85 85 64.8  8.6 74.1 1.4  1.5 77.6 e e e 43 (50.6) <5 years since diagnosis,
FVC >50% pred, DLco 30
e79%. Age >40.
Prednisolone less than
15 mg daily
King et al., e
2011 [22]
Bosentan
(BUILD-3)
209 320 63.2  9.1 63.6 0.5 73.1 47.9 142 (67.9%) e 36 (17.2) <3 years since diagnosis.
No age limits. Excluded if
>5% honeycombing
Prednisolone less than
20 mg daily
Noble et al.,
2011 [10]
Pirfenidone
(CAPACITY)
347 480 60.9 72.6 e 74.6 46.7 232 (66.9%) 17 (5%) 0 (0) <4 years since diagnosis.
Age 40e80. FVC 50%
predicted, DLco 35%
predicted. No
concomitant
immunosuppression
Taniguchi et al., e
2010 [25]
Pirfenidone 104 104 64.7  7.3 77.9 ea 79.1 55.2 83 (79.8%) 13 (12.5%) 5 (4.8) No time limit on
diagnosis, Age 20e75. No
PFT limits. Prednisolone
less than 10 mg daily
IPF research
network e
2010 [29]
Sildenafil 91 49 68.2  9.3 82 1.87  1.93 58.73 26.7 69 (76%) e 0 (0) DLco 35% predicted;
advanced IPF only No
concomitant
immunosuppression
Daniels et al.,
2009 [24]
Imatinib 61 113 67.8 64 e 65.6 39.3 38 (64%) e 0 (0) <3 years since diagnosis.
Age 20e79. FVC 55%
predicted, DLco 35%
pred. No concomitant
immunosuppression
King et al., e
2009 [23]
Interferon gamma-1b
(INSPIRE)
275 407 65.9  7.9 68 e 73.1 47.3 191 (69.4%) 14 (5%) 47 (17.1) <4 years since diagnosis.
Age 40e79. FVC 55%
predicted, DLco 35%
pred. Prednisolone less
than 0.125 mg/kd/day
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King et al., e
2008 [21]
Bosentan (BUILD-1) 84 84 65.1  9.1 63 1.1  1.0 69.5 41.4 e e 11 (13.1) <3 years since diagnosis.
No age limits. FVC >50%
predicted, DLco >30%
Prednisolone less than
15 mg daily
Raghu et al.,
2007 [26]
Etanercept 41 38 65.1  7.1 58.5 1.0  1.1 63.0 36.9 e e 0 (0) <2 years since diagnosis.
No age limits. FVC >55%,
DLco >25% No
concomitant
immunosuppression
Malouf et al.,
2007 [27]
Everolimus 45 90 60.0  9.0 71.1 e 69.0 42.0 e e 12 (26.7) No mention of severity of
previous decline.
Diagnosis of IPF only.
Prednisolone less than
10 mg daily
Raghu et al.,
2004 [20]
Interferon gamma-1b 168 187 63.4  8.6 66 1.0  0.8 64.1 36.8 e 15 (9%) 77 (45.8) No maximum length of
time of diagnosis. Age 20
e79. FVC 50% pred,
DLco 25% Prednisolone
less than 15 mg daily
Azuma et al.,
2004 [28]
Pirfenidone 35 24 64.3  7.6 94 e 78.4 57.7 32 (92%) 3 (9%) 8 (22.9) No time limit for
diagnosis. Age 20e75. No
guidance on PFTs.
Prednisolone less than
10 mg daily
Total number of Participants in placebo arms Z 1631 Total follow-up across trials Z 2067.7 patient/years Total number taking corticosteroids Z 266.
a No data for average time since diagnosis, though more than a third had IPF for >3 yr.
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Table 2 Comparison of baseline characteristics of par-
ticipants within trials excluding severe disease compared
with those including severe disease (2a) and within trials
including immunosuppressant use compared with those
excluding patients on immunosuppression (2b).
2a
Patients with
severe disease
excluded (9 trials,
1374 patients)
Patients with
severe disease
included (4 trials,
257 patients)
Age (years) 63.8 67.1
% male 71.2% 80.2%
Time since diagnosis
(years)
0.9 2.2
FVC (% predicted) 72.3% 67.5%
Diffusion capacity
(% predicted)
45.4% 37.8%
% Ever smokers 68.9% 81.6%
% Current smokers 6.6% 3.3%
% Receiving steroids 15.9% 43.4%
2b
Immunosuppressant
use (9 trials,
1091 patients)
No immuno-
suppressant use
(3 trials, 449
patients)
Age (years) 64.8 62.2
% male 70.5 75.7
Time since diagnosis
(years)
1.1 1.0
FVC (% predicted) 72.2% 70.1%
Diffusion capacity
(% predicted)
41.9% 39.8%
% Ever smokers 73.3% 60.1%
% Current smokers 6.9% 5%
% Receiving steroids 26.7% 0%
380 C.P. Atkins et al.included in the quantitative meta-analysis, involving 1631
patients, and 2067.7 years of patient follow-up (Tables
1e5).
No paper scored less than 3 points using the Jadad score,
indicating good methodological quality. Assessment of bias
suggested low risk of bias through study design, with only
two trials judged as ‘unclear’ for sequence generation, as
found in the Jadad score. Publication bias was not felt to be
an issue due to the use of placebo arms of trials only.
Nine trials included only mild-to-moderate disease
severity [10,11,20e26], three trials included all disease se-
verities [8,27,28], and one trial [29] included severe disease
only. Nine trials included patients who were concurrently
taking immunosuppression [8,11,20e23,25,27,28], three did
not [10,24,26] and one did not specify [29]. In total, 291
patients within these trials (26.7%) were taking
corticosteroids.
Outcomes
We included thirteen trials with a total of 1631 patients, and
2067.7 years of patient follow-up. Baseline characteristicsfor the pooled patient groups are shown in Table 2a
(comparing trials excluding severe disease with those
enrolling all disease severities) and Table 2b (comparing
trials allowing concurrent use of low-dose immunosuppres-
sion and those not allowing immunosuppression). Therewere
no major baseline differences in patients enrolled in trials
allowing and excluding prednisolone use. Baseline differ-
ences between trials excluding severe disease and those
including all severities showed that those including severe
disease were older (67.1 yrs vs 63.8 yrs), had been diagnosed
for longer (2.2 vs 0.9 yrs), had lower baseline FVC and DLco
values, and were more likely to have already commenced
immunosuppression (43.4% vs 15.9%).
There were a total of 190 fatalities in the placebo arms
of the trials, thus giving a standardised mortality rate of
91.9 deaths per 1000 patient/years follow-up. The relative
proportions of patients dying per year by study are shown in
Fig. 1. All but one of the trials stated how many patients
died from respiratory problems, which totaled 142 patients
from twelve trials, thus giving a standardised event rate of
70.3 deaths per 1000 patient/years due to respiratory
events.
The mortality rate was significantly lower overall in tri-
als that only included mild and moderate disease severities
as compared to trials where severe patients were included
(IRR 0.42, 95% CI 0.30e0.59,p < 0.0001). The overall
standardised mortality rate was 78.6 deaths per 1000 pa-
tient/years in eight trials that recruited only patients with
mild-to-moderate disease as compared to 188.6 fatalities
per 1000 patient/years overall in four trials that included
patients with severe disease (Table 5). The proportion of
fatal events per year in each trial and the pooled average
from the random effect meta-analysis are shown in Figs. 1
and 2. Key features illustrated in the Forest plots are the
extent of heterogeneity between studies, and the differ-
ence between studies that recruited only mild to moderate
disease (annual proportion of fatalities 8%; 95% CI 5.2%e
12%) as compared to those that included patients with se-
vere disease (annual proportion of fatalities 15.4%; 95% CI
9.1%e23.1%).
We observed that trials permitting concomitant use of
low dose immunosuppression had higher rates of death
compared to those where participants were not taking
immunosuppression alongside placebo (Table 4). All-cause
mortality rates were 95.8 deaths per 1000 patient/years
overall in ten trials allowing immunosuppression, compared
with 72.9 deaths per 1000 patient/years overall in three
trials enrolling those not on immunosuppression (IRR 1.31,
95% CI 0.93e1.88).
In studies reporting infective events, the standardised
rate of lower respiratory tract infections was 172.5 events
per 1000 patient/years in ten trials reporting the outcome,
whereas the overall standardised rate of pneumonia was
45.6 events per 1000 patient/years across eight studies
(Fig. 3). Six of the studies allowing concurrent use of low-
dose steroids and three of the studies not allowing steroid
use reported infective events. Incidence of lower respira-
tory tract infections was significantly higher in the group
that allowed immunosuppression, at 227.1 respiratory in-
fections per 1000 patient/years, compared with rates in the
non-immunosuppressant group of 63.4 per 1000 patient/
years (p < 0.0001, IRR 3.58, 95% C.I. 2.56e5.13). A similar
Table 3 Standardised event rates.
Trial Investigated agent Lower respiratory
tract infections
Pneumonia (if listed
separately)
Death(All cause
mortality)
Death (respir ory
cause mortal )
Acute exacerbations IPF progression
Actual
events
(%)
Events
per 1000
patient/
years
Actual
events
(%)
Events
per 1000
patient/
years
Actual
events
(%)
Events
per 1000
patient/
years
Actual
events
(%)
Eve ts
pe 000
pa nt/
yea s
Actual
events
(%)
Events per
1000
patient/
years
Actual
events
(%)
Events
per 1000
patient/
years
Shulgina et al., e
2012 [8]
Co-trimoxazole 46 (53.5) 534.9 8 (9.3) 93.0 19 (22.1) 220.9 16 (18.6) 186 1 No data e No data e
Richieldi et al., e
2011 [11]
BIBF-1120 11 (12.9) 129.4 e e 12 (14.1) 141.2 8 (9.4) 94 1 No data e 37 (44) 435.3
King et al., e 2011 [22] Bosentan
(BUILD-3)
64 (30.6) 200.0 12 (5.7) 37.5 6 (2.9) 18.8 3 (1.4) 9 4 6 (2.9) 18.8 82 (36.4) 256.3
Noble et al., 2011 [10] Pirfenidone
(CAPACITY)
22 (6.3) 45.8 15 (4.3) 31.2 34 (9.8) 70.8 28 (8.1) 58 3 No data e 106 (31) 220.6
Taniguchi et al., e
2010 [25]
Pirfenidone e e e e 4 (3.8) 38.5 1 (1.0) 9 6 4 (3.8) 38.5 58 (55.8) 557.7
IPF clinical research
network e 2010 [29]
Sildenafil 2 (2.2) 40.8 1 (1.1) 20.4 11 (12.1) 224.5 e e 4 (4.4) 81.6 5 (5.5) 102.0
Daniels et al., 2009 [24] Imatinib 7 (11.5) 62.2 7 (11.5) 62.1 10 (16.4) 88.8 7 (11.5) 62 2 1 (1.6) 8.9 19 (25.3) 168.7
King et al., e 2009 [23] Interferon
gamma-1b
(INSPIRE)
76 (27.6) 186.6 13 (4.7) 31.9 39 (14.2) 95.8 32 (11.6) 78 6 15 (5.5) 36.8 21 (8) 51.6
King et al., e 2008 [21] Bosentan
(BUILD-1)
e e e e 8 (9.5) 95.2 8 (9.5) 95 2 3 (3.6) 35.7 30 (36.1 357.1
Raghu et al., 2007 [26] Etanercept 11 (26.8) 290.7 e e 2 (4.9) 52.9 2 (4.9) 52 9 No data e 22 (53.6) 581.3
Malouf et al., 2007 [27] Everolimus 10 (22.2) 111.1 10 (22.2) 111.1 16 (35.6) 177.8 13 (28.9) 144 4 No data e 14 (31.1) 155.6
Raghu et al., 2004 [20] Interferon
gamma-1b
60 (35.7) 320.2 13 (7.7) 69.4 28 (16.7) 149.4 23 (13.7) 122 7 No data e 87 (52) 464.3
Azuma et al., 2004 [28] Pirfenidone e e e e 1 (2.9) 41.3 1 (2.9) 41 3 5 (14.3) 206.3 No data e
Overall 309 172.5b 79 45.6b 190 91.9b 142 68 7b 29 26.3b 481 245.7b
Percentage of Patients suffering event 21.9%a e 6.2%a e 11.6% e 9.2%a e 3.4%a e 31.9%a e
a Percentage of patients from trials reporting this outcome.
b Averages (means) are weighted relative to the size of each study.
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Table 4 Comparison of trials permitting immunosuppression vs no immunosuppression allowed.
Trial Investigated
Agent
Death (All cause
mortality)
Death (Respiratory
cause mortality)
Acute exacerbations Lower Respiratory
Tract Infections
Pneumonia IPF Progression
Actual
Events
(%)
Events
per 1000
patient/
years
Actual
Events
(%)
Events
per 1000
patient/
years
Actual
Events
(%)
Events
per 1000
patient/
years
Actual
Events
(%)
Events
per 1000
patient/
years
Actual
Events
(%)
Events
per 1000
patient/
years
Actual
Events
(%)
Events
per 1000
patient/
years
Immunosuppression Permitted (1388 patient/years follow up)
Shulgina et al., e
2012 [8]
Co-trimoxazole 19 (22.1) 220.9 16 (18.6) 186.1 e e 46 (53.5) 534.9 8 (9.3) 93.0 No data e
Richieldi et al., e
2011 [11]
BIBF-1120 12 (14.1) 141.2 8 (9.4) 94.1 e e 11 (12.9) 129.4 e e 37 (44) 435.3
King et al., e
2011 [22]
Bosentan
(BUILD-3)
6 (2.9) 18.8 3 (1.4) 9.4 6 (2.9) 18.8 64 (30.6) 200.0 12 (5.7) 37.5 82 (36.4) 256.3
Taniguchi et al., e
2010 [25]
Pirfenidone 4 (3.8) 38.5 1 (1.0) 9.6 4 (3.8) 38.5 e e e e 58 (55.8) 557.7
King et al., e
2009 [23]
Interferon
gamma-1b
(INSPIRE)
39 (14.2) 95.8 32 (11.6) 78.6 15 (5.5) 36.8 76 (27.6) 186.6 13 (5) 31.92 21 (8) 51.6
King et al., e
2008 [21]
Bosentan
(BUILD-1)
8 (9.5) 95.2 8 (9.5) 95.2 3 (3.6) 35.7 e e e e 30 (36.1) 357.1
Malouf et al.,
2007 [27]
Everolimus 16 (35.6) 177.8 13 (28.9) 144.4 e e 10 (22.2) 111.1 10 (22) 111.1 14 (31.1) 155.6
Raghu et al.,
2004 [20]
Interferon
gamma-1b
28 (16.7) 149.4 23 (13.7) 122.7 e e 60 (35.7) 320.2 13 (8) 69.4 87 (52) 464.3
Azuma et al.,
2004 [28]
Pirfenidone 1 (2.9) 41.3 1 (2.9) 41.3 5 (14.3) 206.3 e e e e No data e
Overall 133 95.84 105 75.66 33 35.1 267 227.1 56 51.4 329 257.5
Immunosuppression Not Permitted (631 patient/years follow up)
Noble et al.,
2011 [10]
Pirfenidone
(CAPACITY)
34 (9.8) 70.8 28 (8.1) 58.3 e e 22 (6.3) 45.8 15 31.2 106 (31) 220.6
Daniels et al.,
2009 [24]
Imatinib 10 (16.4) 88.8 7 (11.5) 62.2 1 (1.6) 8.9 7 (11.5) 62.2 7 62.1 19 (25.3) 168.7
Raghu et al.,
2007 [26]
Etanercept 2 (4.9) 52.9 2 (4.9) 52.9 e e 11 (26.8) 290.7 e e 22 (53.6) 581.3
Overall 46 72.9 37 58.6 1 (1.6) 8.9 40 63.4 22 37.1 147 233.0
Incidence rate ratio (comparing
groups)
1.31
(0.93e1.88,
p Z 0.11)
1.29
(0.88e1.93,
p Z 0.18)
3.93
(0.65e
159.95,
p Z 0.14)
3.58
(2.56e5.13,
p < 0.0001)
1.39
(0.83e2.38,
p Z 0.19)
1.11
(0.91e1.35),
p Z 0.31
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Table 5 Comparison of trials including mild and moderate disease severities only with those permitting all disease seve ies.
Trial Investigated
Agent
Death (All cause
mortality)
Death (Respiratory
cause mortality)
Acute exacerbations Lower Respiratory
Tract Infections
Pneumonia IPF Progression
Actual
Events
(%)
Events
per 1000
patient/
years
Actual
Events
(%)
Events
per 1000
patient/
years
Actual
Events
(%)
Events
per 1000
patient/
years
Actual
Events
(%)
Events
per 1000
patient/
years
Actual
Events
(%)
Events
per 1000
patient/
years
Actual
Events
(%)
Events
per 1000
patient/
years
Patients with severe disease excluded (1818.5 patient/years follow-up)
Richieldi et al., e
2011 [11]
BIBF-1120 12 (14.1) 141.2 8 (9.4) 94.1 e e 11 (12.9) 129.4 e e 37 (44) 435.3
Noble et al.,
2011 [10]
Pirfenidone
(CAPACITY)
34 (9.8) 70.8 28 (8.1) 58.3 e e 22 (6.3) 45.8 15 (4.3) 31.2 106 (31) 220.6
King et al., e
2011 [22]
Bosentan
(BUILD-3)
6 (2.9) 18.8 3 (1.4) 9.4 6 (2.9) 18.8 64 (30.6) 200.0 12 (5.7) 37.5 82 (36.4) 256.3
Taniguchi et al., e
2010 [25]
Pirfenidone 4 (3.8) 38.5 1 (1.0) 9.6 4 (3.8) 38.5 e e e e 58 (55.8) 557.7
King et al., e
2009 [23]
Interferon
gamma-1b
(INSPIRE)
39 (14.2) 95.8 32 (11.6) 78.6 15 (5.5) 36.8 76 (27.6) 186.6 13 (5) 31.92 21 (8) 51.6
Daniels et al.,
2009 [24]
Imatinib 10 (16.4) 88.8 7 (11.5) 62.2 1 (1.6) 8.9 7 (11.5) 62.2 7 (11.5) 62.1 19 (25.3) 168.7
King et al., e
2008 [21]
Bosentan
(BUILD-1)
8 (9.5) 95.2 8 (9.5) 95.2 3 (3.6) 35.7 e e e e 30 (36.1) 357.1
Raghu et al.,
2007 [26]
Etanercept 2 (4.9) 52.9 2 (4.9) 52.9 e e 11 (26.8) 290.7 e e 22 (53.6) 581.3
Raghu et al.,
2004 [20]
Interferon
gamma-1b
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Malouf et al.,
2007 [27]
Everolimus 16 (35.6) 177.8 13 (28.9) 144.4 e e 10 (22.2) 111.1 10 (22) 111.1 14 (31.1) 155.6
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Figure 1 Forest plot showing proportion of mortality per
year across all studies.
Figure 3 Forest plot showing proportion of patients suffering
lower respiratory tract infection per year (all studies).
384 C.P. Atkins et al.trend was seen with the incidence of pneumonias, with an
average incidence in the six trials permitting immunosup-
pression of 51.4 pneumonias per 1000 patient/years,
compared with 37.1 pneumonias/1000 patient/years in two
trials not allowing immunosuppression, although the higher
rate in the trials allowing low-dose immunosuppression was
not statistically significant (IRR 1.39, 95% C.I. 0.83e2.38).
The proportion of lower respiratory tract infections per
year in each trial and the pooled average from the random
effects meta-analysis are shown in Figs. 3 and 4, clearly
displaying the heterogeneity between studies.
Rates of infection were also seen to be higher in studies
including patients with severe disease. In the three trials
reporting rates of lower respiratory tract infections, the
event rate was 257.8 per 1000 patient/years, compared
with 153.9 per 1000 patient/years in those including mild
and moderate disease severities only (IRR 0.60, 95% C.I.
0.45e0.81, p Z 0.0003).
Acute exacerbation rates were captured in six trials,
with a weighted average of 41 acute exacerbations per 1000
patient/years overall. No difference was observed between
trials permitting immunosuppression with those notFigure 2 Forest plot showing proportion of mortality per year (
disease severities included).(incidence rate ratio 3.93. 95% C.I. 0.65e159.95), though
only one trial not permitting immunosuppressant use [10]
quoted rates of acute exacerbations. The study not
permitting immunosuppression use did show the lowest
rates of acute exacerbations of any of the trials. Rates of
acute exacerbations were much lower in trials that
excluded patients with severe disease as compared to trials
where severe patients were included (IRR 0.23, 95% C.I.
0.11e0.55, p < 0.0001).
Progression of disease was similar between trials allow-
ing immunosuppression and those that did not (257.5 vs
233.0 per 1000 patient/years). Although rates were higher
in trials excluding severe disease compared with those
including all disease severities (254.1 vs 136.7 events per
1000 patient/years), only two trials including all disease
severities captured data regarding disease progression,
which included only 136 patients in total and 139 patient/
years of follow-up.
Discussion
From analysis of the placebo arms of clinical trials, we have
shown that there was considerable variation in the mor-
tality rate between trials. Mortality rates were significantlystudies including mild-to-moderate disease severity only vs all
Figure 4 Forest plot showing proportion of patients suffering lower respiratory tract infections per year (trials allowing
immunosuppression vs those allowing no concurrent immunosuppression).
Outcomes from idiopathic pulmonary fibrosis trials 385lower in trials excluding severe disease compared to those
including all disease severities. There were significantly
higher rates of infection in those studies permitting the use
of low-dose corticosteroids versus those not allowing use of
any immunosuppressants. However, rates of infection were
still high in patients not receiving any form of immuno-
suppression. Although reporting of acute exacerbations was
limited, our meta-analysis also suggests that the risk of
these events is increased in patients taking corticosteroids
and in patients with severe disease.
The finding of raised rates of infection was striking. The
suspension of the triple therapy arm of the PANTHER-IPF
trial [12] had previously shown that, patients receiving high
dose prednisolone (0.5 mg/kg), azathioprine and n-ace-
tylcysteine were at an increased risk of death (11% vs 1%)
and hospitalisation (29% vs 8%), but no difference in the
rates of infective events between arms (6% vs 1%,
p Z 0.12). Unexpectedly, in this meta-analysis rates of
respiratory infections were significantly higher even in tri-
als permitting low-dose prednisolone. The association be-
tween low dose immunosuppression and infection is likely
to be stronger than suggested here as not all patients
enrolled in the trials permitting low-dose prednisolone
were on immunosuppression, or the events may not have
been picked up during the course of trial follow-up.
Although a higher rate of infection may have been ex-
pected in the trials allowing concurrent use of immuno-
suppressive drugs [30], a high frequency of lower
respiratory tract infections and pneumonias was also
observed in patients who were enrolled in trials not
allowing immunosuppressant medications. For comparison
with another chronic respiratory disease, the incidence of
pneumonias in patients not taking immunosuppression was
similar to that previously seen in a cohort with severe COPD
[31]. This suggests that IPF itself is a risk factor for the
development of pulmonary infections. The results also
suggest a possible correlation between susceptibility to
infection and underlying disease state. The higher rate of
infections seen in the trials where severe disease was
captured indicates that infections may become increasinglyproblematic in the natural course of the disease as it
progresses.
The findings are in keeping with data from a post-
mortem study of IPF patients which reported that bacte-
rial pneumonia (23% of cases) was the commonest cause of
death and significantly more common than age matched
controls [32], suggesting infections become more frequent
as the disease progresses, and are commonly a terminal
event. Previous research has shown alveolar macrophages
in IPF patients are able to phagocytose bacteria, but
expressed little bacteriocidal or bacteriostatic activity,
leaving them unable to kill facultative intracellular bacte-
ria [33]. These alveolar macrophages normally clear the air
spaces of infectious particles [34], and a loss of function
could predispose to infections.
From epidemiological data, the median survival of IPF
patients is 3.9 years, with a mortality rate of 180 deaths per
1000 patient/years follow-up [35]. This is in stark contrast
to the overall mortality rate seen in the placebo arms of the
clinical trials (91.9 deaths per 1000 patient/years of follow-
up). Separating trials into those including all disease se-
verities had a mortality rate almost identical to that from
epidemiological data (188.6 deaths per 1000 patient/
years), whereas studies excluding these patients had a
much lower mortality rate (78.6 deaths per 1000 patient/
years). It is clear that the mortality rate is highly variable
and dependent on disease severity. Indeed markers of
severity, in particular FVC, are key components to pre-
dictors of mortality The low overall mortality rate seen in
the placebo arms would suggest that it would be difficult to
see a significant difference in this outcome when investi-
gating a new agent in patients with mild-to-moderate dis-
ease [5]. However, the high rates of mortality in unselected
studies or studies of more severe disease suggest that
mortality might be an appropriate outcome measurement
in trials including these patients. Nevertheless, the fre-
quency of fatal events may not increase in a strictly linear
fashion with time, and so extension of the duration of
clinical trials of IPF patients to 2- or 3-year duration may
yield different findings or potentially higher rates than
386 C.P. Atkins et al.which might be expected through simple extrapolation
from one-year (or shorter) duration studies. Disease pro-
gression over this time could potentially have a significant
impact on the mortality rate in a placebo group, but this
would need to be evaluated in an actual clinical trial.
Regardless, these data highlights the importance of
selecting the outcomes of clinical trials of therapeutic en-
tities in light of the entry criteria.
Poor reporting of rates of acute exacerbations prevent a
clear picture of whether immunosuppression use or disease
severity increases the risk of these potentially fatal events
[7]. However the incidence rate was lower in the study not
permitting immunosuppressants than in those permitting
corticosteroid therapy. Incidence rates of acute exacerba-
tions were substantially higher in trials enrolling all disease
severities, which may suggest that these events become
more frequent as the disease advances, or could be related
to the higher rates of low-dose immunosuppression use in
these trials.
No difference was seen in rates of disease progression
(as defined by a reduction in FVC 10% or DLco 15% during
the trials) between trials allowing and excluding low-dose
corticosteroid use, suggesting that although steroids do not
prevent disease progression, they do not increase the
likelihood of the disease progressing. When comparing tri-
als including all disease severities with those only including
mild and moderate severities, only two trials reported rates
of IPF progression in the former group, making it very
difficult to accurately draw any conclusions about whether
progression of disease is more common in trials including
more severe disease. As clinical trials are now tending to
focus on rates of progression (given the previously
mentioned issues with mortality) [5], understanding how
frequently patients in the placebo arms will suffer pro-
gression is clearly important.
The weakness of this review is the absence of individual
patient data. When analysing the frequency of adverse
events and infective events in studies including patients on
corticosteroids, we do not have information on the duration
of corticosteroid use, nor the exact dose (though less than
20 mg of prednisolone). No differences were observed be-
tween the baseline characteristics of patients enrolled in
trials permitting low-dose prednisolone compared with
trials not permitting any immunosuppression (Table 2b) to
account for the differences observed between these
groups. Although there were some differences in baseline
characteristics between studies permitting all disease se-
verities and those excluding severe disease (Table 2a), the
most important explanation of the mortality and infection
rate differences seem to be time since diagnosis, poor
pulmonary function and use of immunosuppression.
Nevertheless, we recognise that infectious complications
and survival outcomes in IPF may be associated with a
diverse range of patient or treatment variables, and that no
single trial may have sufficient sample size to enable sta-
tistical evaluation of all these important variables. Hence,
a comprehensive analysis examining outcomes in key sub-
groups may only be possible through individual patient
meta-analysis, as demonstrated in recent research on
attributable mortality in ventilator-associated pneumonia
where the initial systematic review was subsequently
followed-up by an individual patient data analysis [36,37].This study provides important information for the design
of future clinical trials in IPF. Future studies should consider
the issue of sample size based upon their defined entry
criteria. If patients with severe disease are excluded then
the mortality rate should be expected to be low, and an
alternative primary outcome, such as change in FVC, should
be considered. Further research is needed to look specif-
ically at rates of respiratory infections and possible risk
factors for LRTIs and pneumonias in IPF patients. There may
also be benefit in identifying strategies that may help
reduce the frequency of these infective events.
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